- The European Commission approves AstraZeneca's (NYSE:AZN) Lynparza (olaparib) for the maintenance treatment of adult patients with platinum-resistant relapsed BRCA-mutated (germline and/or somatic) high grade serious epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete response or partial response to platinum-based chemotherapy.
- Olaparib is a poly ADP-ribose polymerase (PARP) inhibitor that exploits DNA repair pathway deficiencies to preferentially kill cancer cells. It is the first PARP inhibitor approved for patients with platinum-sensitive relapsed BRCA-mutated ovarian cancer. Appropriate patients will be identified through a validated diagnostic test.
- The company is investigating the efficacy of olaparib in other cancer types.